BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

Pharming Enrolls First Patient in Japanese APDS Treatment Trial

Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase ...

August 10, 2023 | News

GenScript Expands Peptide Production Capabilities to Include Neoantigen Peptides and APIs

GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has ramped up production of complex and modi...

August 09, 2023 | News

First Patient Dosed in TLX101 Brain Cancer Study for Newly Diagnosed Glioblastoma

IPAX-2 (ClinicalTrials.gov Identifier: NCT05450744) is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with externa...

August 08, 2023 | News

Ascentage Pharma Gets FDA Clearance for Global Phase III Trial of Lisaftoclax in CLL/SLL Patients

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related...

August 07, 2023 | News

US FDA Grants Orphan Drug Status to ABM-1310 for BRAF V600 Glioblastoma

Orphan Drug Designation is a significant recognition bestowed by the FDA to the drugs used in the treatment of rare diseases. This designation intends to e...

August 03, 2023 | News

Doer Biologics Initiates Phase I MAD Trial of DR10624, Receives NMPA IND Approval

The Phase I MAD study is a randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics ...

August 02, 2023 | News

NMPA and FDA Approve First-in-Human Trial for LBL-034 in Multiple Myeloma

This is a first-in-human, single-arm, multicenter, open-label, dose-escalation and expansion clinical study, and plans to enroll patients with relapsed/ref...

August 01, 2023 | News

Everest Medicines Completes Patient Enrollment for Nefecon® China Study

The cOLE study offers an additional 9 months of treatment with Nefecon® to all qualifying patients who have completed the NefIgArd study and will evalu...

August 01, 2023 | News

Lupin Pharmaceuticals Recalls 2 Lots of TydemyTM Due to OOS Results

Lupin Pharmaceuticals Inc. (Lupin) is voluntarily recalling two (2) lots of Tydemy (Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets 3mg/0....

July 31, 2023 | News

Transcenta's Anti-sclerostin Antibody TST002 Approved for Phase II Trial in China for Reduced Bone Density Patients

This study aims to evaluate the safety, tolerability, and pharmacokinetics of TST002(Blosozumab) after single and multiple intravenous administrations in p...

July 31, 2023 | News

RenovoRx and Imugene Join Forces for Oncolytic Virus Therapy Using TAMP Platform

Collaboration will explore trans-arterial delivery of Imugene's CF33 oncolytic virus utilizing RenovoRx's TAMP therapy platform TAMP enables localized, ...

July 25, 2023 | News

China's Mabwell Announces NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

B7-H3 is a member of the B7 ligand family and is overexpressed in most cancer types but expressed at a low level in normal tissues. In malignant tissues, B...

July 24, 2023 | News

Insilico Medicine Nominates Preclinical Candidate for ISM001-055, First Generative AI IPF Drug

Insilico Medicine merges nebulizer device with AI-driven drug discovery; Potential advantages for the inhalation solution include a smaller effe...

July 24, 2023 | News

AstraZeneca's Saphnelo Now Available in Malaysia for Adult Autoantibody-Positive SLE

SLE is a chronic and complex autoimmune condition that can affect any organ, and patients often experience inadequate disease control, long-term organ dama...

July 21, 2023 | News

Stay Connected